ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics LLC announced today that it has been identified and selected by Therapeutic Area Partnerships as a “Top Project to Watch: Most Licensable Products” for the second consecutive year. RetroSense Therapeutics is a privately held biotechnology company at the forefront of developing optogenetic therapies for vision restoration. In October 2014, RetroSense’s lead compound, RST-001 was granted orphan drug designation for retinitis pigmentosa, a genetic disease characterized by deteriorating vision and blindness.
Help employers find you! Check out all the jobs and post your resume.
